Paclitaxel -Protein Bound Particles (PBP)

Prior to Initiation of Therapy

• Experienced Physician/Equipped Facility in the use of chemotherapeutic agents
• Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

Avoidance with Low Neutrophil Counts

• Should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts < 1500>3
• To monitor for the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed during therapy

Non-Substitution

• DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS
  

Package Inserts

Paclitaxel